Killer Immunoglobulin-Like Receptor 2DS2 (KIR2DS2), KIR2DL2-HLA-C1, and KIR2DL3 as Genetic Markers for Stratifying the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients.
cytomegalovirus
human leukocyte antigen
kidney transplantation
killer-cell immunoglobulin-like receptor
lymphocytopenia
natural killer cell
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jan 2019
28 Jan 2019
Historique:
received:
18
12
2018
revised:
10
01
2019
accepted:
24
01
2019
entrez:
31
1
2019
pubmed:
31
1
2019
medline:
5
6
2019
Statut:
epublish
Résumé
Infection with cytomegalovirus (CMV) remains a major problem in kidney transplant recipients, resulting in serious infectious complications and occasionally mortality. Accumulating evidence indicates that natural killer cell immunoglobulin-like receptors (KIRs) and their ligands affect the susceptibility to various diseases, including viral infections (e.g., CMV infection). We investigated whether KIR genes and their ligands affect the occurrence of CMV infection in a group of 138 kidney transplant recipients who were observed for 720 days posttransplantation. We typed the recipients for the presence of KIR genes (human leukocyte antigen C1 [HLA-C1], HLA-C2, HLA-A, HLA-B, and HLA-DR1) by polymerase chain reaction with sequence-specific primers. The multivariate analysis revealed that the lack of
Identifiants
pubmed: 30696053
pii: ijms20030546
doi: 10.3390/ijms20030546
pmc: PMC6387393
pii:
doi:
Substances chimiques
Genetic Markers
0
HLA-C Antigens
0
Receptors, KIR
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4778-83
pubmed: 10781084
J Infect Dis. 2001 Dec 1;184(11):1461-4
pubmed: 11709790
J Immunol. 2002 Nov 1;169(9):5118-29
pubmed: 12391228
Immunol Rev. 2002 Dec;190:40-52
pubmed: 12493005
J Exp Med. 2003 Apr 7;197(7):933-8
pubmed: 12668644
Tissue Antigens. 2003 Jul;62(1):79-86
pubmed: 12859599
Annu Rev Immunol. 2005;23:225-74
pubmed: 15771571
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13224-9
pubmed: 16141329
Blood. 2006 Feb 1;107(3):1230-2
pubmed: 16239436
Am J Transplant. 2008 Jun;8(6):1312-7
pubmed: 18444913
Clin J Am Soc Nephrol. 2008 Sep;3(5):1526-33
pubmed: 18701615
Am J Transplant. 2008 Dec;8(12):2674-83
pubmed: 19032228
Biol Blood Marrow Transplant. 2009 Mar;15(3):315-25
pubmed: 19203722
Liver Transpl. 2009 Oct;15(10):1209-16
pubmed: 19790140
Liver Transpl. 2009 Nov;15(11):1557-63
pubmed: 19877200
Am J Transplant. 2010 May;10(5):1228-37
pubmed: 20353469
Am J Transplant. 2011 Jun;11(6):1302-7
pubmed: 21486386
Biol Blood Marrow Transplant. 2011 Nov;17(11):1662-72
pubmed: 21596150
Transpl Int. 2011 Dec;24(12):1170-8
pubmed: 21902725
Am J Transplant. 2013 Feb;13(2):376-82
pubmed: 23205887
Am J Transplant. 2013 Mar;13 Suppl 4:93-106
pubmed: 23465003
Am J Transplant. 2014 Jan;14(1):156-62
pubmed: 24369024
Transplantation. 2014 Jul 27;98(2):187-94
pubmed: 24621539
Genes Immun. 2014 Oct;15(7):495-9
pubmed: 25008861
Liver Transpl. 2014 Dec;20(12):1497-507
pubmed: 25205044
Transplantation. 2015 Jul;99(7):1506-13
pubmed: 25427165
J Infect. 2015 Nov;71(5):561-70
pubmed: 26183297
Sci Immunol. 2017 Sep 15;2(15):
pubmed: 28916719
Immunology. 2018 Apr;153(4):523-531
pubmed: 29067686
Transfusion. 2018 Apr;58(4):1028-1035
pubmed: 29446443
Transplantation. 2018 Jun;102(6):900-931
pubmed: 29596116
BMC Infect Dis. 2018 Apr 16;18(1):179
pubmed: 29661141
Oncotarget. 2018 Apr 3;9(25):17523-17532
pubmed: 29707126
Oncotarget. 2018 Apr 13;9(28):19650-19661
pubmed: 29731972
Transplantation. 2018 Nov;102(11):1795-1814
pubmed: 30028786
J Infect Dis. 2018 Nov 5;218(12):2006-2015
pubmed: 30099516
J Med Virol. 1994 Feb;42(2):188-92
pubmed: 7512614
Immunity. 1997 Dec;7(6):753-63
pubmed: 9430221
J Immunol. 1998 Jul 15;161(2):571-7
pubmed: 9670929